Back to Search Start Over

Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction

Authors :
Maida Bada
Stefano Boccasile
Michele De Tursi
Mino Rizzo
Salvatore Micali
Pasquale Ditonno
Marcello Scarcia
Cosimo De Nunzio
Paolo Chiodini
Anastasia Laudisi
Luigi Schips
Giampaolo Bianchi
Oscar Selvaggio
Luca Topazio
Eugenio Martorana
Silvana Giacinti
Pierluigi Bove
Luca Cindolo
Clara Natoli
Giuseppe Carrieri
Giuseppe Mario Ludovico
Maurizio Valeriani
Pietro Castellan
Cindolo, Luca
Natoli, Clara
De Nunzio, Cosimo
De Tursi, Michele
Valeriani, Maurizio
Giacinti, Silvana
Micali, Salvatore
Rizzo, Mino
Bianchi, Giampaolo
Martorana, Eugenio
Scarcia, Marcello
Ludovico, Giuseppe Mario
Bove, Pierluigi
Laudisi, Anastasia
Selvaggio, Oscar
Carrieri, Giuseppe
Bada, Maida
Castellan, Pietro
Topazio, Luca
Boccasile, Stefano
Ditonno, Pasquale
Chiodini, Paolo
Schips, Luigi
Source :
Clinical genitourinary cancer. 15(5)
Publication Year :
2017

Abstract

This article highlights the possible role of “patient-reported outcomes” in the evaluation of a new therapy. Abiraterone acetate is a novel treatment for metastatic prostate cancer characterized by good safety and oncologic efficacy. Few studies have investigated patients' satisfaction with treatment. Our data show that abiraterone acetate is associated with good satisfaction with treatment and that patient's satisfaction can be a predictor of good oncologic outcomes. Introduction Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA. Materials and Methods This was a retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC. Patients were treated with AA until disease progression, death, or unacceptable toxicity. Evaluation was performed at baseline and every 4 weeks by means of physical examination and laboratory studies. Eastern Cooperative Oncology Group score, pain symptoms, treatment-related toxicity, prostate-specific antigen (PSA), and overall and progression-free survival were recorded. Satisfaction with treatment was investigated at 6 months by means of a 4-point arbitrary scale. Results One-hundred twenty-eight patients were enrolled. Patients' satisfaction with treatment was “greatly improved” in 36.1% of patients and “improved” in 32.4% of them. Patients with higher satisfaction had lower baseline and final PSA values (P < .05), lower PSA levels at 12 weeks (P = .080), and less pain symptoms and lower Brief Pain Inventory scores (P = .001). Satisfaction with treatment was significantly correlated with baseline PSA level (P = .018), presence of pain (P = .007), duration of androgen deprivation therapy >12 months (P = .025), and number of hormonal manipulations (P = .051). Progression-free survival significantly correlated with patient satisfaction (P < .001). Conclusion AA is safe and well tolerated in chemonaive mCRPC patients, ensures good oncological and PROs. Patient's satisfaction is a predictor of progression-free survival.

Details

ISSN :
19380682
Volume :
15
Issue :
5
Database :
OpenAIRE
Journal :
Clinical genitourinary cancer
Accession number :
edsair.doi.dedup.....33a2baa66d2fac7bc7cca437fc99c6df